» Articles » PMID: 11587517

Magnetic Resonance Imaging of Bone Marrow Changes in Gaucher Disease During Enzyme Replacement Therapy: First German Long-term Results

Overview
Journal Skeletal Radiol
Specialties Orthopedics
Radiology
Date 2001 Oct 6
PMID 11587517
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Since 1991, enzyme replacement therapy (ERT) has been available for patients with Gaucher disease in Germany. The aim of this study was to analyse the MR pattern of bone marrow involvement and response to ERT in Gaucher disease type I.

Patients And Design: Thirty patients with Gaucher disease type I had MRI examinations prior to initiation of ERT with alglucerase/imiglucerase and during follow-up. Median MR follow-up and duration of ERT were 36 months. Coronal T1- and T2-weighted spin-echo images of the lower extremities were obtained to evaluate changes in the appearance of yellow marrow. MR images were categorized as having either a homogeneous (type A) or non-homogeneous patchy (type B) appearance of bone involvement and response to ERT was assessed by two radiologists.

Results: Overall, 19 of 30 patients (63%) showed an increased signal intensity on T1- and T2-weighted images after 36 months of ERT, consistent with partial reconversion of fatty marrow during treatment. Focal bone lesions surrounded by a low signal intensity (SI) rim did not respond to ERT, suggesting bone infarcts. Of the 11 patients with bone infarcts (low SI rim lesion), 82% had the non-homogeneous type B pattern (P=0.0021). In 86% of patients with splenectomy, bone infarcts were seen (P<0.05).

Conclusions: MRI using T1- and T2-weighted spin-echo sequences is a valuable, non-invasive method for monitoring bone marrow response in patients receiving ERT. A non-homogeneous patchy signal intensity of bone marrow involvement correlates with the presence of bone infarcts (P=0.0021).

Citing Articles

Successful treatment of Gaucher disease type 1 by enzyme replacement therapy over a 10-year duration in a Japanese pediatric patient: A case report.

Oto Y, Inoue T, Nagai S, Tanaka S, Itabashi H, Shiraisihi M Exp Ther Med. 2021; 21(3):246.

PMID: 33603854 PMC: 7851597. DOI: 10.3892/etm.2021.9677.


Gaucher Disease in Bone: From Pathophysiology to Practice.

Hughes D, Mikosch P, Belmatoug N, Carubbi F, Cox T, Goker-Alpan O J Bone Miner Res. 2019; 34(6):996-1013.

PMID: 31233632 PMC: 6852006. DOI: 10.1002/jbmr.3734.


Magnetic resonance imaging and BMB score in the evaluation of bone involvement in Gaucher's disease patients.

de Mello R, Mello M, Pessanha L Radiol Bras. 2015; 48(4):216-9.

PMID: 26379319 PMC: 4567359. DOI: 10.1590/0100-3984.2014.0068.


Bone marrow involvement in Gaucher disease at MRI : what long-term evolution can we expect under enzyme replacement therapy?.

Fedida B, Touraine S, Stirnemann J, Belmatoug N, Laredo J, Petrover D Eur Radiol. 2015; 25(10):2969-75.

PMID: 25875285 DOI: 10.1007/s00330-015-3715-2.


Imaging of Gaucher disease.

Simpson W, Hermann G, Balwani M World J Radiol. 2014; 6(9):657-68.

PMID: 25276309 PMC: 4176783. DOI: 10.4329/wjr.v6.i9.657.